News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Egenix, Inc. Announces New Director


5/22/2013 6:15:02 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MILLBROOK, N.Y., May 21, 2013 /PRNewswire/ -- Donald Fresne, President and CEO of Egenix, Inc., is pleased to announce the appointment of Arshad Siddiqui, Ph.D. to its Board of Directors. Dr. Siddiqui received a Ph.D. in chemistry from the University of Waterloo, Ontario, Canada. He was an associate director of antiviral chemistry at Shire BioChem Pharma where he was responsible for the development of several clinical candidates in the area of HIV, HBV and HCV. Dr. Siddiqui relocated to NeoGenesis Pharmaceuticals, Cambridge, MA as a senior director of the medicinal chemistry. He was director of medical chemistry at Schering Plough and Merck in Cambridge, MA. Dr. Siddiqui's careers span over 22 years, and include contributions to discovery of Epivir and multiple clinical stage compounds. Dr. Siddiqui is a co-recipient of Prix-Galien, Canada (1996) and has published over 61 research articles and over 68 patents. Dr. Siddiqui will be a great and welcomed asset to the Egenix Board.

Egenix is a privately held, New York-based biotechnology company focused on the development of innovative cancer therapeutics. The company's therapeutic platform technology consists of small molecule drugs applicable for the treatment and prevention of a broad spectrum of cancers. Our lead drug candidates inhibit the "translation initiation factor" efF4E, specifically blocking production of multiple cancer promoting proteins and promoting apoptosis (programmed cell death) and upregulation of tumor suppressor genes. The company licensed this technology from Harvard Medical School in 2007. eIF4E is an attractive cancer therapeutic target because every function necessary for cancer growth and metastasis is influenced or mediated by a gene product that is regulated by this translation initiation factor. Data from human cancer xenograft studies using two of our lead compounds tested against breast cancer and melanoma demonstrated 100% tumor inhibition and 20% to 30% tumor reduction. For more information visit www.egenixinc.com.

SOURCE Egenix, Inc.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES